Skip to main content
SpringerLink
Log in

Young Patients With Chronic Lymphocytic Leukemia

  • Chapter
Chronic Lymphocytic Leukemia

Part of the book series: Contemporary Hematology ((CH))

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. In view of the mean age of CLL patients at presentation, the frequently indolent clinical course, and the overall restricted treatment options, for many years there has been only somewhat limited interest in this disease, and management has been largely conservative. However, the overall scenario and approach has changed significantly during the last few years, for the following reasons: (1) the progressive and constant increase in the “biological” age of CLL patients; (2) the availability of new drugs, namely, the purine analogs, which have a marked antileukemic action in CLL; (3) the knowledge that transplantation may have a role and may impact on this disease; (4) the evidence that monoclonal antibodies (MAbs) may be utilized in CLL; and (5) the progressive recognition of biological features that have prognostic implications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Spier CM, Kjeldsberg CR, Head DR, Di Fiore KC, Tudor B. Chronic lymphocytic leukemia in young adults. Am J Clin Pathol 1985; 84: 675–678.

    PubMed  CAS  Google Scholar 

  2. Bennett JM, Raphael B, Oken MM, Rubin P, Silber R. The prognosis of chronic lymphocytic leukemia under age 50 years. Nouv Rev Fr Hematol 1988; 30: 411–412.

    PubMed  CAS  Google Scholar 

  3. Montserrat E, Gomis F, Vallespi T, et al Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood 1991; 78: 1545–1551.

    PubMed  CAS  Google Scholar 

  4. Pangalis GA, Reverter JC, Boussiotis VA, Montserrat E. Chronic lymphocytic leukemia in younger adults: preliminary results of a study based on 454 patients. IWCLL/Working Group. Leuk Lymphoma 1991; 5: 175–181.

    Article  Google Scholar 

  5. De Rossi G, Mandelli F, Covelli A, et al. Chronic lymphocytic leukemia (CLL) in younger adults: a retrospective study of 133 cases. Hematol Oncol 1989; 7: 127–131.

    Article  PubMed  Google Scholar 

  6. Dhodapkar M, Tefferi A, Su J, Phyliky RL. Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study. Leukemia 1993; 7: 1232–1235.

    PubMed  CAS  Google Scholar 

  7. Molica S, Brugiatelli M, Callea V, et al. Comparison of younger versus older B-cell chronic lymphocytic leukaemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. Eur J Haematol 1994; 52: 216–221.

    Article  PubMed  CAS  Google Scholar 

  8. De Lima M, O’Brien S, Lerner S, Keating MJ. Chronic lymphocytic leukemia in the young patient. Semin Oncol 1998; 25: 107–116.

    PubMed  Google Scholar 

  9. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of “young” chronic lymphocytic leucemia patients: a single institution study of 204 cases. Blood 1999; 94: 448–454.

    PubMed  CAS  Google Scholar 

  10. Seymour JF, Robertson LE, O’Brien S, Lerner S, Keating MJ. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma 1995; 18: 493–496.

    Article  PubMed  CAS  Google Scholar 

  11. Sgambati MT, Linet MS, Devesa SS. Chronic lymphocytic leukemia. Epidemiological, familial, and genetic aspects. In: Cheson BD, ed. Chronic Lymphoid Leukemias. 2nd ed. Marcel Dekker, New York, 2001, pp. 33–62.

    Google Scholar 

  12. Diehl LF, Karnell LH, Menck HR. The National Cancer data base on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999; 86: 2684–2692.

    Article  PubMed  CAS  Google Scholar 

  13. Rai RR, Dohner H, Keating MJ, Montserrat E. Chronic lymphocytic leukemia: case-based session. Hematology (Am Soc Hematol Educ Program) 2001: 140–156.

    Google Scholar 

  14. Bennett JM, Catovsky D, Daniel MT, et al. The French-American-British (FAB) Cooperative Group. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol 1989; 42: 567–584.

    Article  PubMed  CAS  Google Scholar 

  15. Catovsky D, Foa R. The Lymphoid Leukaemias. Butterworths, London, 1990.

    Google Scholar 

  16. Criel A, Verhoef G, Vlietinck R, et al. Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases. Br J Haematol 1997; 97: 383–391.

    Article  PubMed  CAS  Google Scholar 

  17. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640–1645.

    PubMed  CAS  Google Scholar 

  18. Moreau EJ, Matutes E, A’Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997; 108: 378–382.

    PubMed  CAS  Google Scholar 

  19. Pezzella F, Munson PJ, Miller KD, Goldstone AH, Gatter KC. The diagnosis of low B-cell neoplasm in bone marrow trephines. Br J Haematol 2000; 108: 369–376.

    Article  PubMed  CAS  Google Scholar 

  20. Ries LAG, Kosary CL, Hankley BF, Miller BA, Clegg LX, Edwards BK. SEER Cancer Statistics Review, 19731996. NIH Publication No. 99–2789. National Cancer Institute, Bethesda, MD, 1999, pp. 262–283.

    Google Scholar 

  21. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

    Article  PubMed  Google Scholar 

  22. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.

    PubMed  CAS  Google Scholar 

  23. Damle JN, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.

    PubMed  CAS  Google Scholar 

  24. Kröber A, Seiler T, Leupolt E, Döhner H, Stilgenbauer S. IgVH mutated and unmutated B-CLL tumors show distinct genetic aberration patterns. Blood 2000; 96 (Suppl 1): 835a.

    Google Scholar 

  25. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutation are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023–1029.

    Article  PubMed  CAS  Google Scholar 

  26. Montserrat E, Vinolas N, Reverter JC, Rozman C. Natural history of chronic lymphocytic leukemia: on the progression and prognosis of early stages. Nouv Rev Fr Hematol 1998; 30: 359–361.

    Google Scholar 

  27. Catovsky D, Richards S, Fooks J, Hamblin TJ. CLL trials in the United Kingdom: MRC trial 1, 2 and 3. Leuk Lymphoma 1991; 5 (suppl 14): 105.

    Google Scholar 

  28. Dighiero G, Maloum K, Desablens B, et al. for The French Cooperative Group on Chronic Lymphocytic Leukemia. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998; 338: 1506–1514.

    Article  PubMed  CAS  Google Scholar 

  29. CLL Trialist’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999; 91: 861–868.

    Article  Google Scholar 

  30. Keating MJ, O’Brien S, Kantarjian H, et al Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878.

    Google Scholar 

  31. The French Cooperative Group on CLL, Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432–1438.

    Google Scholar 

  32. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757.

    Article  PubMed  CAS  Google Scholar 

  33. O’Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414–1420.

    PubMed  Google Scholar 

  34. Montserrat E. Developing risk-adapted treatment strategies for chronic lymphocytic leukemia. In: Cheson BD, ed. Chronic Lymphoid Leukemias, 2nd ed. Marcel Dekker, New York, 2001, pp. 377–392.

    Google Scholar 

  35. Montserrat E, Esteve J, Schmitz N, et al. Autologous stem-cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL): results in 107 patients. Blood 1999; 94 (suppl 1): 397a.

    Google Scholar 

  36. Dreger P, von Neuhoff N, Sonnen R, et al: Efficacy and prognostic implications of early autologous stem cell transplantation for poor-risk chronic lymphocytic leukemia. Blood 2000; 96 (suppl 1): 483.

    Google Scholar 

  37. Horowitz MM, Montserrat E, Sobocinski K, et al. for the Chronic Leukemia Working Committee, International Bone Marrow Transplant Registry (IBMTR) and the Autologous Blood and Marrow Transplant Registry (ABMTR). Hematopoietic stem-cell transplantation (SCT) for chronic lymphocytic leukemia (CLL). Blood 2000; 96 (suppl 1): 522a

    Google Scholar 

  38. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease. Leukemia 2001; 15: 445–451.

    Article  PubMed  CAS  Google Scholar 

  39. Dreger P, van Biezen A, Brand R, et al Outcome after autologous stem cell transplantation for CLL: a prognostic factor analysis from the EBMT database. Hematol J 2001; 1 (suppl 1): 219a.

    Google Scholar 

  40. Khouri I, Keating M, Körbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabinebased nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    PubMed  CAS  Google Scholar 

  41. Khouri I, Munsell M, Zajzi S, et al. Comparable survival for nonablative and ablative allogeneic transplantation for chronic lymphocytic leukemia (CLL): the case for early intervention. Blood 2000; 96 (suppl 1): 205a.

    Google Scholar 

  42. Anaissie EJ, Kontoyiannis DP, O’Brien S, Kantarjian H, Robertson L, Keating MJ. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Int Med 1998; 129: 559–566.

    PubMed  CAS  Google Scholar 

  43. Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001; 19: 3611–3621.

    PubMed  CAS  Google Scholar 

  44. Sudhoff T, Arning M, Schneider W. Prophylactic strategies to meet infectious complications in fludarabinetreated CLL. Leukemia 1997; 11 (suppl 2): S38–41.

    PubMed  Google Scholar 

  45. O’Brien S, Kantarjian H, Beran M, et al. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997; 11: 1631–1635.

    Article  PubMed  Google Scholar 

  46. Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992; 84: 1422–1142.

    Article  PubMed  CAS  Google Scholar 

  47. Hisada M, Biggar RJ, Greene MH, Fraumeni JF Jr, Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98: 1979–1981.

    Article  PubMed  CAS  Google Scholar 

  48. Robertson LE, Pugh W, O’Brien S, et al. Richter’s syndrome: a report on 39 patients. J Clin Oncol 1993; 11: 1985.

    PubMed  CAS  Google Scholar 

  49. Morrison VA, Rai KR, Peterson BL, et al. Transformation to Richter’s syndrome or to prolymphocytic leukemia (PLL) and other second hematologic malignancies in patients with chronic lymphocytic leukemia (CLL): an Intergroup Study (CALGB 9011). Blood 1999; 94; 539a.

    Google Scholar 

  50. Desablens B, Garidi R, Fernandes J, et al. Does fludarabine increase the risk of Richter’s syndrome (RS) among chronic lymphocytic leucemia? Haematologica 1999; 84: 259.

    Google Scholar 

  51. Cheson BD, Vena DA, Barret J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphocytic leukemias. J Clin Oncol 1999; 17: 2454–2460.

    PubMed  CAS  Google Scholar 

  52. Welsh TM, Thompson J, Lim S. Chronic lymphocytic leukemia in pregnancy. Leukemia 2000; 14: 1155.

    Article  PubMed  CAS  Google Scholar 

  53. Saifollahi J, Rouhani M, Roth AJ, Holland JC. Psychological aspects of chronic lymphocytic leukemias. In: Cheson BD, ed. Chronic Lymphoid Leukemias. 2nd ed. Marcel Dekker, New York, 2001, pp. 593–608.

    Google Scholar 

Download references

Authors
  1. Francesca R. Mauro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robin Foa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Hematology/Oncology, Veterans Affairs Medical Center, Augusta, GA, USA

    Guy B. Faguet MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mauro, F.R., Foa, R. (2004). Young Patients With Chronic Lymphocytic Leukemia. In: Faguet, G.B. (eds) Chronic Lymphocytic Leukemia. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-412-2_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-412-2_23

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-355-8

  • Online ISBN: 978-1-59259-412-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation